OBSV - ObsEva SA

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

14.71

-0.22 (-1.47%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	14.93
Open	14.99
Bid	13.48 x 1000
Ask	15.15 x 800
Day's Range	14.00 - 15.00
52 Week Range	5.90 - 20.35
Volume	66,385
Avg. Volume	100,388

Market Cap	535.977M
Beta	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-2.21
Earnings Date	Aug 13, 2018 - Aug 17, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	29.75

Trade prices are not sourced from all markets

All

News

Press Releases

GlobeNewswire4 days ago
ObsEva Announces Pricing of Follow-on Public Offering
June 20, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, announced today the pricing of an underwritten public offering of 4,750,000 common shares at a price of $15.39 per share, before underwriting discounts and commissions. In addition, ObsEva has granted the underwriters a 30-day option to purchase up to an additional 712,500 common shares at the public offering price, less the underwriting discounts and commissions. ObsEva anticipates the total gross proceeds from the offering (before deducting the underwriting discounts and commission and estimated offering expenses) will be $73.1 million, excluding any exercise of the underwriters' option to purchase additional shares. ObsEva intends to use the net proceeds from the proposed offering primarily to continue the development of its three new chemical entities in its pipeline and invest in pre-commercial activates in support of its pipeline assets, and for working capital and other general corporate purposes.
GlobeNewswire4 days ago
ObsEva Announces Pricing of Follow-on Public Offering
June 20, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, announced today the pricing of an underwritten public offering of 4,750,000 common shares at a price of $15.39 per share, before underwriting discounts and commissions. In addition, ObsEva has granted the underwriters a 30-day option to purchase up to an additional 712,500 common shares at the public offering price, less the underwriting discounts and commissions. ObsEva anticipates the total gross proceeds from the offering (before deducting the underwriting discounts and commission and estimated offering expenses) will be $73.1 million, excluding any exercise of the underwriters` option to purchase additional shares. ObsEva intends to use the net proceeds from the proposed offering primarily to continue the development of its three new chemical entities in its pipeline and invest in pre-commercial activates in support of its pipeline assets, and for working capital and other general corporate purposes.
GlobeNewswire6 days ago
ObsEva Announces Launch of Proposed Follow-on Public Offering
June 18, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, announced today the launch of a proposed underwritten public offering of 4,750,000 common shares. ObsEva intends to use the net proceeds from the proposed offering primarily to continue the development of its three new chemical entities in its pipeline and invest in pre-commercial activates in support of its pipeline assets, and for working capital and other general corporate purposes. J.P. Morgan Securities LLC, Credit Suisse Securities (USA) LLC and Jefferies LLC are acting as joint bookrunning managers.
GlobeNewswire6 days ago
ObsEva Announces Launch of Proposed Follow-on Public Offering
June 18, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, announced today the launch of a proposed underwritten public offering of 4,750,000 common shares. ObsEva intends to use the net proceeds from the proposed offering primarily to continue the development of its three new chemical entities in its pipeline and invest in pre-commercial activates in support of its pipeline assets, and for working capital and other general corporate purposes. J.P. Morgan Securities LLC, Credit Suisse Securities (USA) LLC and Jefferies LLC are acting as joint bookrunning managers.
GlobeNewswire6 days ago
ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis
Partial suppression of estradiol with moderate dose (75mg) of linzagolix demonstrated highly significant reduction of pain and improvement of patient well-being High dose (200mg) of linzagolix achieves ...
GlobeNewswire6 days ago
ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis
Partial suppression of estradiol with moderate dose of linzagolix demonstrated highly significant reduction of pain and improvement of patient well-being. High dose of linzagolix achieves full estradiol ...
GlobeNewswire9 days ago
ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis-Associated Pain on Monday June 18, 2018
Geneva, Switzerland and Boston, MA - June 15, 2018 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious ...
GlobeNewswire9 days ago
ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis-Associated Pain on Monday June 18, 2018
Geneva, Switzerland and Boston, MA- June 15, 2018- ObsEva SA, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that ...
GlobeNewswire23 days ago
ObsEva SA to Seek SIX Share Listing
Geneva, Switzerland and Boston, MA -June 1, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced its intention to request the listing of its shares on SIX Swiss Exchange under SIX's international reporting standard. "Last years listing on the NY based NASDAQ was a major step for the company as it provides access to capital to pursue the development of our rich, late-stage clinical, product portfolio, hence moving closer to address the needs of millions of women worldwide and continue to create value for our shareholders" said Ernest Loumaye, MD, PhD, OB/GYN, CEO and Co-Founder of ObsEva. "Today as a Swiss company, we are proud and thrilled to announce our intention to be listed on SIX.
GlobeNewswire23 days ago
ObsEva SA to Seek SIX Share Listing
Geneva, Switzerland and Boston, MA -June 1, 2018 - ObsEva SA (OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, today announced its intention to request the listing of its shares on SIX Swiss Exchange under SIX`s international reporting standard. "Last years listing on the NY based NASDAQ was a major step for the company as it provides access to capital to pursue the development of our rich, late-stage clinical, product portfolio, hence moving closer to address the needs of millions of women worldwide and continue to create value for our shareholders" said Ernest Loumaye, MD, PhD, OB/GYN, CEO and Co-Founder of ObsEva. "Today as a Swiss company, we are proud and thrilled to announce our intention to be listed on SIX.
GlobeNewswire24 days ago
ObsEva SA to Participate in Jefferies Global Healthcare Conference June 5-8, 2018
Geneva, Switzerland and Boston, MA -May 31, 2018 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious ...
GlobeNewswire24 days ago
ObsEva SA to Participate in Jefferies Global Healthcare Conference June 5-8, 2018
Geneva, Switzerland and Boston, MA- May 31, 2018- ObsEva SA, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that ...
Thomson Reuters StreetEventslast month
Edited Transcript of OBSV.O earnings conference call or presentation 16-May-18 12:00pm GMT
Q1 2018 Obseva SA Earnings Call
Motley Foollast month
ObsEva SA Ordinary Shares (OBSV) Q1 2018 Earnings Conference Call Transcript
OBSV earnings call for the period ending March 31, 2018.
Simply Wall St.last month
With A -121.60% Earnings Drop, Did ObsEva SA (NASDAQ:OBSV) Really Underperform?
After looking at ObsEva SA’s (NASDAQ:OBSV) latest earnings announcement (31 December 2017), I found it useful to revisit the company’s performance in the past couple of years and assess thisRead More...
GlobeNewswirelast month
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
-Key First Quarter 2018 Clinical Milestones Achieved. Patient randomization completed in Phase 2 b EDELWEISS trial of OBE2109 in Endometriosis, results expected by the end of Q2: 18, and Primary endpoint ...
GlobeNewswirelast month
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
-Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109 in Endometriosis, results expected by the end of Q2:18, and Primary endpoint ...
GlobeNewswirelast month
Consolidated Research: 2018 Summary Expectations for Care, Unilever, CECO Environmental, Carter's, ObsEva SA, and ViewRay — Fundamental Analysis, Key Performance Indications
NEW YORK, May 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Care.com, ...
GlobeNewswire2 months ago
ObsEva SA to Hold First Quarter 2018 Financial Results and Business Update Call on May 16, 2018
Geneva, Switzerland and Boston, MA- May 8, 2018- ObsEva SA, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that ...
GlobeNewswire2 months ago
ObsEva SA to Hold First Quarter 2018 Financial Results and Business Update Call on May 16, 2018
Geneva, Switzerland and Boston, MA - May 8, 2018 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious ...
GlobeNewswire2 months ago
ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109)
Geneva, Switzerland and Boston, MA- 23 April 2018- ObsEva SA, a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise ...
GlobeNewswire2 months ago
ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109)
Geneva, Switzerland and Boston, MA - 23 April 2018 - ObsEva SA (OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy, today announced it will make presentations at the 4th Congress of the Society of Endometriosis and Uterine Disorders (SEUD) taking place April 26 - 28, 2018 in Florence (Italy).
GlobeNewswire2 months ago
ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City
Geneva, Switzerland and Boston, MA - April 16, 2018 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious ...
GlobeNewswire2 months ago
ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City
Geneva, Switzerland and Boston, MA- April 16, 2018- ObsEva SA, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that ...
GlobeNewswire3 months ago
Analysis: Positioning to Benefit within Fortress Transportation and Infrastructure Investors, Turquoise Hill Resources, FactSet Research, Shaw Communications, El Pollo Loco, and ObsEva SA — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, March 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...